TY - JOUR
T1 - Guidelines for therapy of autoimmune liver disease
AU - Ishibashi, Hiromi
AU - Komori, Atsumasa
AU - Shimoda, Shinji
AU - Gershwin, M. Eric
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2007/5
Y1 - 2007/5
N2 - The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.
AB - The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.
UR - http://www.scopus.com/inward/record.url?scp=34249912673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249912673&partnerID=8YFLogxK
U2 - 10.1055/s-2007-979472
DO - 10.1055/s-2007-979472
M3 - Review article
C2 - 17520519
AN - SCOPUS:34249912673
SN - 0272-8087
VL - 27
SP - 214
EP - 226
JO - Seminars in Liver Disease
JF - Seminars in Liver Disease
IS - 2
ER -